Results 21 to 30 of about 150,706 (165)

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors

Oncology Reviews, 2011
Tyrosine kinase inhibitors (TKIs) are the mainstay for treatment of chronic myelogenous leukemia (CML). Imatinib was the first TKI approved for use in CML, but resistance to this therapy has emerged as a significant issue, and second-line options are ...
Michael G. Martin, John F. DiPersio, Geoffrey L. Uy   +2 more
doaj   +1 more source

Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang

Cancer Biology & Medicine, 2016
Acute myeloid leukemia (AML) is characterized by the accumulation of circulating immature blasts that exhibit uncontrolled growth, lack the ability to undergo normal differentiation, and have decreased sensitivity to apoptosis.
Hong-Sheng Zhou, Bing Z. Carter, Michael Andreeff   +2 more
doaj   +1 more source

Targeting Bruton’s Tyrosine Kinase in CLL

Frontiers in Immunology, 2021
Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
Inhye E. Ahn, Jennifer R. Brown
doaj   +1 more source

Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML

Translational Oncology, 2022
Tyrosine kinase inhibitors (TKIs) are established drugs in the therapy of FLT3-ITD mutated acute myeloid leukemia (AML). However, acquired mutations, such as D835 in the tyrosine kinase domain (FLT3-ITD/D835), can induce resistance to TKIs.
Kotoko Yamatani, Tomohiko Ai, Kaori Saito, Koya Suzuki, Atsushi Hori, Sonoko Kinjo, Kazuho Ikeo, Vivian Ruvolo, Weiguo Zhang, Po Yee Mak, Bogumil Kaczkowski, Hironori Harada, Kazuhiro Katayama, Yoshikazu Sugimoto, Jered Myslinski, Takashi Hato, Takashi Miida, Marina Konopleva, Yoshihide Hayashizaki, Bing Z. Carter, Yoko Tabe, Michael Andreeff   +21 more
doaj   +1 more source

High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure

Leukemia Research Reports, 2014
Dual differentiation therapy with arsenic trioxide and tretinoin (all-trans-retinoic acid; ATRA) for the management of low and intermediate risk acute promyelocytic leukemia has recently been recommended by the National Comprehensive Cancer Network. Some
Morgan B. Smith, Elizabeth A. Griffiths, James E. Thompson, Eunice S. Wang, Meir Wetzler, Craig W. Freyer   +5 more
doaj   +1 more source

Supplementary Statistical Section from Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I–Related Plexiform Neurofibromas [PDF]

, 2023
Lauren H. Boal, John Glod, Melissa J. Spencer, M. Kasai, Joanne Derdak, Eva Dombi, Mark A. Ahlman, Daniel W. Beury, Melinda S. Merchant, Christianne Persenaire, David J. Liewehr, Seth M. Steinberg, Brigitte C. Widemann, Rosandra N. Kaplan   +13 more
openalex   +2 more sources

Protocol for monitoring clonal hematopoiesis in transgenic mouse models using multispectral imaging

STAR Protocols
Summary: Clonal hematopoiesis involves the clonal expansion of hematopoietic cells, potentially progressing into hematological malignancies. Here, we present a protocol for the development and characterization of two mouse models designed to simulate ...
Priyanka Khanna, Lauren B. Ostermann, Shayaun Khazaei, Ran Zhao, Michael Andreeff, Rasoul Pourebrahim   +5 more
doaj   +1 more source

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

Haematologica, 2017
Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo, Huaxian Ma, Vivian R. Ruvolo, Xiaorui Zhang, Hong Mu, Wendy Schober, Ivonne Hernandez, Miguel Gallardo, Joseph D. Khoury, Jorge Cortes, Michael Andreeff, Sean M. Post   +11 more
doaj   +1 more source

Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

npj Breast Cancer
Gangliosides are acidic glycosphingolipids involved in cell-adhesion, signal-transduction and tumor progression. GD3 synthase (GD3S/ST8SIA1), a key enzyme in ganglioside biosynthesis, is upregulated in many cancers, including GD2+ breast cancer stem-like
Vivek Anand, Bolutyfe Oderinde, Maryam Siddiqui, Anudishi Tyagi, Jenny Borgman, Chong Wu, Michael Andreeff, V. Lokesh Battula   +7 more
doaj   +1 more source

Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis

Haematologica, 2018
The bone marrow microenvironment, also known as the bone marrow niche, is a complex network of cell types and acellular factors that supports normal hematopoiesis.
Phuong M. Le, Michael Andreeff, Venkata Lokesh Battula   +2 more
doaj   +1 more source